Impact of educational strategies in positioning Samarium-153 EDTMP as a treatment for metastatic bone pain
- 1. Center of Nuclear Medicine - Instituto Peruano de Energia Nuclear - IPEN-INEN, Lima 34 (Peru)
Description
To educate is a difficult task but its results make efforts worthwhile. Many patients in Peru suffer from intractable bone pain due to metastases. Since 1993 radionuclides were used to palliate bone pain due to metastases in Peru. First, with the help of the IAEA, Peru participated in a clinical trial using Phosphorus 32 and Strontium 89. Then, efforts were performed to produce Samarium 153 EDMTP locally, which was achieved in 1995. Nevertheless, years passed and Samarium use did not increase proportionally to the needs of people with cancer and bone pain, mainly the poor. Educational strategies have been proven useful for delivering solutions to many health problems in other diseases and also in cancer. Health education makes patients and their relatives assume responsible care of their problems. The purpose of this work was to increase Samarium EDTMP use as palliative treatment in patients with bone pain due to metastases, using educational strategies as means to change attitudes towards this health problem. In September 2003, a task group conducted studies in order to apply several methods to achieve the goal of increasing Samarium EDTMP use. Educational strategies employed were performed to provide verbal and written information to patients, physicians, medical students, residents, pain specialists, oncologists and neurologists, as well as general public. Verbal information included radio interviews, television spots and a phone number (in charge of two secretaries, prepared for answering and if not possible, a physician was in charge of attending patient consultation), e-mail and a web page for consultation. Written material was delivered to several newspapers, including clinical use of Samarium, possibilities of being elected for treatment, benefits and risks and a photography of the product. Politics of the institution producing Samarium changed, in order to achieve minimum cost of the product and it was delivered to all publics at the lowest cost for a year, which has finished in December 2004. Three television spots were delivered to public: 'Hello, Doctor', which has a morning audience and in two interviews in news programs, with high rating performance. Five interviews were given in radio programs, one of them was for a feminine audience, three for general public and the other two with national impact. In every program a web page, an e-mail and a telephone number were given for consultation. In Nuclear Medicine Centers in Lima telephone calls have been received since the beginning of the campaign every day, up to date. In a year, a monthly conference was delivered to physicians. Samarium EDTMP treatment increased substantially after the campaign. The more significant means in mass media for changing management were patient education, continuous meetings with specialists and one of the television spots used ('Hello, doctor'), which continues to be delivered in the closed circuit TV network of the social security system. We conclude that repetitive educational strategies have a positive impact in delivering radiopharmaceuticals for bone pain palliation to patients with bone metastases
Availability note (English)
Also available online: www.wjnm.orgAdditional details
Publishing Information
- Journal Title
- World Journal of Nuclear Medicine
- Journal Volume
- 4
- Journal Issue
- suppl.1
- Journal Page Range
- p. S43-S44
- ISSN
- 1450-1147
Conference
- Title
- International conference on radiopharmaceutical therapy
- Acronym
- ICRT-2005
- Dates
- 11-14 Oct 2005
- Place
- Limassol (Cyprus)
INIS
- Country of Publication
- International Atomic Energy Agency (IAEA)
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 36097306
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- BRACHYTHERAPY; CLINICAL TRIALS; COST; MEDICAL PERSONNEL; METASTASES; NEOPLASMS; PAIN; PATIENTS; PERU; PHOSPHORUS 32; RADIOPHARMACEUTICALS; SAMARIUM 153; STRONTIUM 89
- Descriptors DEC
- ALKALINE EARTH ISOTOPES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; DAYS LIVING RADIOISOTOPES; DEVELOPING COUNTRIES; DISEASES; DRUGS; EVEN-ODD NUCLEI; INTERMEDIATE MASS NUCLEI; ISOTOPES; LABELLED COMPOUNDS; LATIN AMERICA; LIGHT NUCLEI; MATERIALS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; PERSONNEL; PHOSPHORUS ISOTOPES; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; RARE EARTH NUCLEI; SAMARIUM ISOTOPES; SOUTH AMERICA; STRONTIUM ISOTOPES; SYMPTOMS; TESTING; THERAPY
Optional Information
- Notes
- Available in abstract form only; 1 fig